Personalized tobramycin dosing in children with cystic fibrosis: an AUC 24 -guided approach
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00278-25 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Kiera H Harwood und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, The University of Melbourne, , Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Tobramycin, Cystic Fibrosis, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Tobramycin is commonly used for the treatment of pulmonary exacerbations in children with cystic fibrosis (CF). Currently, a standard dose of 10 mg/kg daily is used in all children. We aim to develop a population pharmacokinetic (popPK) model of tobramycin in children with CF and determine the: (i) effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on tobramycin pharmacokinetics (PK); (ii) attainment of the commonly used serum steady state area under the concentration-time curve target (AUC 24,ss ) of 80–110 mg/L⋅h with standard dosing; and (iii) generate an optimized fully individualized dosing strategy to improve target attainment. Multicenter prospective observational study of children with CF aged 0–19 years receiving IV tobramycin who had ≥1 serum concentration measured. A popPK model was developed using nonlinear mixed-effect modeling, and simulations were performed to assess study aims. Overall, 63 children had 450 serum tobramycin concentrations. A one-compartment popPK model, including age, weight, a renal maturation model, and estimated glomerular filtration rate as covariates, was developed. With standard dosing, 1/3 of children achieved the target AUC 24,ss with younger children (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics, The University of Melbourne, , Parkville, Victoria, Australia.
- Antimicrobials Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
- Certara, Princeton, New Jersey, USA.
- Department of Respiratory and Sleep Medicine, Royal Children's Hospital, Parkville, Victoria, Australia.
- Respiratory Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
- The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
ORCID-Profile: Kiera H Harwood, Indy Sandaradura, Amanda Gwee
Zitieren
APA
Harwood, K. H., Duffull, S., Shanthikumar, S., Lei, A., Ranganathan, S., Robinson, P., Sandaradura, I., Lai, T., & Gwee, A. (2025). Personalized tobramycin dosing in children with cystic fibrosis: an AUC 24 -guided approach. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00278-25
Vancouver
Harwood KH, Duffull S, Shanthikumar S, Lei A, Ranganathan S, Robinson P, et al. Personalized tobramycin dosing in children with cystic fibrosis: an AUC 24 -guided approach. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00278-25
BibTeX
@article{Harwood2025,
author = {Harwood, Kiera H and Duffull, Stephen and Shanthikumar, Shivanthan and Lei, Alice and Ranganathan, Sarath and Robinson, Phil and Sandaradura, Indy and Lai, Tony and Gwee, Amanda},
title = {Personalized tobramycin dosing in children with cystic fibrosis: an AUC 24 -guided approach},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00278-25}
}
EUVIMED